Eli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
finance.yahoo.comEli Lilly announced clinical trial results for its experimental obesity drug retatrutide on May 22, 2026. The drug produced an average weight loss of 70 pounds among study participants over 80 weeks, according to the company. Eli Lilly stated that retatrutide outperformed its current obesity treatments Zepbound and Wegovy in the trial.
The company presented the findings during a public announcement.
No further details on side effects or regulatory timelines were included in the initial report. The results position retatrutide as a potential next-generation option in the obesity treatment market.
Key Facts
Potential Impact
- 01
Eli Lilly may seek regulatory approval for retatrutide based on the trial data.
- 02
Patients and physicians could gain access to a new obesity medication option.
Transparency Panel
Related Stories
France 24Zambia’s Kabwe Residents Sue Mining Company Over Lead Contamination
Children in Kabwe, Zambia, show blood lead levels above World Health Organization limits after decades of mining. An estimated 140,000 women and children have joined a class-action lawsuit against Anglo American South Africa Limited.
citizen.co.zaEbola Outbreak in Eastern DRC Kills at Least 240 Since Early May
The virus has spread from Ituri province into other eastern DRC regions and Uganda. Health workers report reduced international aid and limited local resources as they attempt to contain transmission.
manilatimes.netOutbreaks of hantavirus and Ebola prompt U.S. quarantine and travel measures
The U.S. government ordered quarantines after a hantavirus outbreak on a cruise ship and imposed new traveler restrictions during an Ebola outbreak in Africa. Federal agencies stated that response operations continue despite recent staffing reductions at health agencies.